SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it has completed the previously announced sale of shares of its Series A 3.6% convertible preferred stock pursuant to a registered direct offering representing gross proceeds of approximately $13.5 million. The preferred stock is convertible into shares of Cytori’s common stock at the option of the investors at a conversion price of $0.52. Cytori also issued warrants to purchase an aggregate of 25,961,541 shares of Cytori’s common stock at an exercise price of $0.5771 per share in the offering.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
